Parithera
Private Company
Total funding raised: $2.8M
Overview
Parithera is an early-stage biotech leveraging a proprietary platform for real-time, functional single-cell analysis to tackle the challenge of tumor heterogeneity. By analyzing individual cells within the tumor microenvironment as they respond to perturbations, the company seeks to identify novel targets and resistance mechanisms that are invisible to bulk genomic approaches. This deep profiling capability is designed to fuel a pipeline of precision oncology and rare disease programs, positioning Parithera at the intersection of advanced diagnostics and therapeutic discovery. The company is privately held, pre-revenue, and operating in the globally competitive but high-potential field of single-cell biology and cancer therapeutics.
Technology Platform
Proprietary platform for real-time, functional single-cell analysis, designed to monitor live individual cells over time under perturbation to decode tumor heterogeneity and identify novel therapeutic targets and resistance mechanisms.
Funding History
1Opportunities
Risk Factors
Competitive Landscape
Parithera competes in the broad single-cell analysis market dominated by tool companies like 10x Genomics, BD, and Fluidigm. Its therapeutic discovery focus places it against other single-cell-driven biotechs (e.g., Celsius Therapeutics) and a wide array of AI/ML-based drug discovery platforms. Differentiation hinges on its real-time, functional readout capability versus static genomic profiling.